| 聂建华,李 顺,张书源.CDK4/6抑制剂治疗消化道肿瘤的研究进展[J].肿瘤学杂志,2021,27(10):805-812. |
| CDK4/6抑制剂治疗消化道肿瘤的研究进展 |
| Progress on CDK4/6 Inhibitors for Gastrointestinal Cancer |
| 投稿时间：2020-10-09 |
| DOI：10.11735/j.issn.1671-170X.2021.10.B003 |
|
 |
| 中文关键词: CDK4/6抑制剂 消化道肿瘤 靶向治疗 联合治疗 |
| 英文关键词:CDK4/6 inhibitors gastrointestinal cancer target therapy combination therapy |
| 基金项目:国家自然科学基金（81872435，81672930） |
|
| 摘要点击次数: 786 |
| 全文下载次数: 127 |
| 中文摘要: |
| 摘 要：CDK4/6抑制剂（CDK4/6 inhibitors，CDK4/6i）通过调控Rb/E2F通路，诱导细胞周期停滞，抑制细胞增殖，发挥抗肿瘤作用，被FDA批准用于乳腺癌的治疗，并在多个瘤种中被广泛研究。在消化道肿瘤相关研究中，CDK4/6i表现出较好的抗肿瘤活性，并可与化疗、靶向治疗、免疫治疗和放疗等产生良好的协同效果。全文现就CDK4/6i近年在消化道肿瘤的研究进展作一综述。 |
| 英文摘要: |
| Abstract： CDK4/6 inhibitors(CDK4/6i) can arrest the cell cycle and inhibit cell proliferation through regulating the Rb/E2F pathway， which have been approved by FDA for treatment of breast cancer and also widely studied in other tumor types. In gastrointestinal cancer， CDK4/6i has shown excellent antitumor activity with optimal synergistic effect with chemotherapy， target therapy， immunotherapy and radiotherapy. This article reviews the progress on CDK4/6i for treatment of gastrointestinal cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |